Testing Experimental Compounds against Leishmaniasis in Laboratory Animal Model Systems.
Abstract
Pentostam and parasite dose responses have been determined for, and three WRAIR experimental compounds have been tested against visceral and mucocutaneous leishmaniasis. In addition, the conditions for screening compounds against mucocutaneous leishmaniasis caused by Leishmania braziliensis braziliensis M2904 (WR464) in male BALB/cByJ mice are presented. The major findings for screening against L. donovani Khartoum are: 1. Amastigotes, stationary primary (PCP) or subcultured (SP) promastigo-tes from Schneider's drosophila medium (cSDM) yield equivalent liver burdens in mice. This allows 3 separate screening experiments from one hamster donor, increasing efficiency of testing. 2. The ED90 for Pentostam in this model is 10 mg/kg/day (mkd) x 5. This is 5 times less than previouslyu determined for Sudan strain L. donovani. 3. A single total dose of Pentostam is as effective as multiple doses. 4. Parasitic cure is obtained at 80 mkd x 5. 5. None of the three experimental compounds tested is competitive with Pentostam, although they are better tolerated than previously tested drugs. 6. Male mice are more sensitive to drug treatment than are females.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 1983
- Accession Number
- ADA172465
Entities
People
- Jan S. Keithly
Organizations
- Weill Cornell Medicine